New cancer clinical trial: IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer

Published on: August 31, 2018 at 12:00PM
Conditions:   Recurrent Hepatocellular Carcinoma;   Refractory Liver Carcinoma;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IVA Hepatocellular Carcinoma AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions:   Drug: Cyclophosphamide;   Biological: IRX-2;   Biological: Nivolumab
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting
https://ift.tt/2ot8Rgv